UBS lowered the firm’s price target on DexCom (DXCM) to $95 from $106 and keeps a Buy rating on the shares. DexCom’s solid sales beat overshadowed by margin weakness, but the firm remains confident in a sustainable mid-to-high teens sales growth outlook, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: